Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity

Valentina Noemi Madia, Antonella Messore, Luca Pescatori, Francesco Saccoliti, Valeria Tudino, Alessandro De Leo, Martina Bortolami, Luigi Scipione, Roberta Costi, Silvia Rivara, Laura Scalvini, Marco Mor, Fabiana Fosca Ferrara, Emiliano Pavoni, Giuseppe Roscilli, Giuliana Cassinelli, Ferdinando M Milazzo, Gianfranco Battistuzzi, Roberto Di Santo, Giuseppe Giannini

Research output: Contribution to journalArticle

Abstract

Heparanase is the sole mammalian enzyme capable of cleaving glycosaminoglycan heparan sulfate side chains of heparan sulfate proteoglycans. Its altered activity is intimately associated with tumor growth, angiogenesis, and metastasis. Thus, its implication in cancer progression makes it an attractive target in anticancer therapy. Herein, we describe the design, synthesis, and biological evaluation of new benzazoles as heparanase inhibitors. Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives 13a, 14d, and 15 that showed IC50 0.16-0.82 μM. Molecular docking studies were performed to rationalize their interaction with the enzyme catalytic site. Importantly, invasion assay confirmed the antimetastatic potential of compounds 14d and 15. Consistently with its ability to inhibit heparanase, compound 15 proved to decrease expression of genes encoding for proangiogenic factors such as MMP-9, VEGF, and FGFs in tumor cells.

Original languageEnglish
Pages (from-to)6918-6936
Number of pages19
JournalJournal of Medicinal Chemistry
Volume61
Issue number15
DOIs
Publication statusPublished - Aug 9 2018

Fingerprint

Neoplasms
Heparan Sulfate Proteoglycans
Heparitin Sulfate
Enzymes
Glycosaminoglycans
Matrix Metalloproteinases
Vascular Endothelial Growth Factor A
Inhibitory Concentration 50
Catalytic Domain
Neoplasm Metastasis
Gene Expression
Amino Acids
Growth
heparanase
Therapeutics

Cite this

Madia, V. N., Messore, A., Pescatori, L., Saccoliti, F., Tudino, V., De Leo, A., ... Giannini, G. (2018). Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity. Journal of Medicinal Chemistry, 61(15), 6918-6936. https://doi.org/10.1021/acs.jmedchem.8b00908

Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity. / Madia, Valentina Noemi; Messore, Antonella; Pescatori, Luca; Saccoliti, Francesco; Tudino, Valeria; De Leo, Alessandro; Bortolami, Martina; Scipione, Luigi; Costi, Roberta; Rivara, Silvia; Scalvini, Laura; Mor, Marco; Ferrara, Fabiana Fosca; Pavoni, Emiliano; Roscilli, Giuseppe; Cassinelli, Giuliana; Milazzo, Ferdinando M; Battistuzzi, Gianfranco; Di Santo, Roberto; Giannini, Giuseppe.

In: Journal of Medicinal Chemistry, Vol. 61, No. 15, 09.08.2018, p. 6918-6936.

Research output: Contribution to journalArticle

Madia, VN, Messore, A, Pescatori, L, Saccoliti, F, Tudino, V, De Leo, A, Bortolami, M, Scipione, L, Costi, R, Rivara, S, Scalvini, L, Mor, M, Ferrara, FF, Pavoni, E, Roscilli, G, Cassinelli, G, Milazzo, FM, Battistuzzi, G, Di Santo, R & Giannini, G 2018, 'Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity', Journal of Medicinal Chemistry, vol. 61, no. 15, pp. 6918-6936. https://doi.org/10.1021/acs.jmedchem.8b00908
Madia VN, Messore A, Pescatori L, Saccoliti F, Tudino V, De Leo A et al. Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity. Journal of Medicinal Chemistry. 2018 Aug 9;61(15):6918-6936. https://doi.org/10.1021/acs.jmedchem.8b00908
Madia, Valentina Noemi ; Messore, Antonella ; Pescatori, Luca ; Saccoliti, Francesco ; Tudino, Valeria ; De Leo, Alessandro ; Bortolami, Martina ; Scipione, Luigi ; Costi, Roberta ; Rivara, Silvia ; Scalvini, Laura ; Mor, Marco ; Ferrara, Fabiana Fosca ; Pavoni, Emiliano ; Roscilli, Giuseppe ; Cassinelli, Giuliana ; Milazzo, Ferdinando M ; Battistuzzi, Gianfranco ; Di Santo, Roberto ; Giannini, Giuseppe. / Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity. In: Journal of Medicinal Chemistry. 2018 ; Vol. 61, No. 15. pp. 6918-6936.
@article{462aca51cd2342cdba71af9461f0e903,
title = "Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity",
abstract = "Heparanase is the sole mammalian enzyme capable of cleaving glycosaminoglycan heparan sulfate side chains of heparan sulfate proteoglycans. Its altered activity is intimately associated with tumor growth, angiogenesis, and metastasis. Thus, its implication in cancer progression makes it an attractive target in anticancer therapy. Herein, we describe the design, synthesis, and biological evaluation of new benzazoles as heparanase inhibitors. Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives 13a, 14d, and 15 that showed IC50 0.16-0.82 μM. Molecular docking studies were performed to rationalize their interaction with the enzyme catalytic site. Importantly, invasion assay confirmed the antimetastatic potential of compounds 14d and 15. Consistently with its ability to inhibit heparanase, compound 15 proved to decrease expression of genes encoding for proangiogenic factors such as MMP-9, VEGF, and FGFs in tumor cells.",
author = "Madia, {Valentina Noemi} and Antonella Messore and Luca Pescatori and Francesco Saccoliti and Valeria Tudino and {De Leo}, Alessandro and Martina Bortolami and Luigi Scipione and Roberta Costi and Silvia Rivara and Laura Scalvini and Marco Mor and Ferrara, {Fabiana Fosca} and Emiliano Pavoni and Giuseppe Roscilli and Giuliana Cassinelli and Milazzo, {Ferdinando M} and Gianfranco Battistuzzi and {Di Santo}, Roberto and Giuseppe Giannini",
year = "2018",
month = "8",
day = "9",
doi = "10.1021/acs.jmedchem.8b00908",
language = "English",
volume = "61",
pages = "6918--6936",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "15",

}

TY - JOUR

T1 - Novel Benzazole Derivatives Endowed with Potent Antiheparanase Activity

AU - Madia, Valentina Noemi

AU - Messore, Antonella

AU - Pescatori, Luca

AU - Saccoliti, Francesco

AU - Tudino, Valeria

AU - De Leo, Alessandro

AU - Bortolami, Martina

AU - Scipione, Luigi

AU - Costi, Roberta

AU - Rivara, Silvia

AU - Scalvini, Laura

AU - Mor, Marco

AU - Ferrara, Fabiana Fosca

AU - Pavoni, Emiliano

AU - Roscilli, Giuseppe

AU - Cassinelli, Giuliana

AU - Milazzo, Ferdinando M

AU - Battistuzzi, Gianfranco

AU - Di Santo, Roberto

AU - Giannini, Giuseppe

PY - 2018/8/9

Y1 - 2018/8/9

N2 - Heparanase is the sole mammalian enzyme capable of cleaving glycosaminoglycan heparan sulfate side chains of heparan sulfate proteoglycans. Its altered activity is intimately associated with tumor growth, angiogenesis, and metastasis. Thus, its implication in cancer progression makes it an attractive target in anticancer therapy. Herein, we describe the design, synthesis, and biological evaluation of new benzazoles as heparanase inhibitors. Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives 13a, 14d, and 15 that showed IC50 0.16-0.82 μM. Molecular docking studies were performed to rationalize their interaction with the enzyme catalytic site. Importantly, invasion assay confirmed the antimetastatic potential of compounds 14d and 15. Consistently with its ability to inhibit heparanase, compound 15 proved to decrease expression of genes encoding for proangiogenic factors such as MMP-9, VEGF, and FGFs in tumor cells.

AB - Heparanase is the sole mammalian enzyme capable of cleaving glycosaminoglycan heparan sulfate side chains of heparan sulfate proteoglycans. Its altered activity is intimately associated with tumor growth, angiogenesis, and metastasis. Thus, its implication in cancer progression makes it an attractive target in anticancer therapy. Herein, we describe the design, synthesis, and biological evaluation of new benzazoles as heparanase inhibitors. Most of the designed derivatives were active at micromolar or submicromolar concentration, and the most promising compounds are fluorinated and/or amino acids derivatives 13a, 14d, and 15 that showed IC50 0.16-0.82 μM. Molecular docking studies were performed to rationalize their interaction with the enzyme catalytic site. Importantly, invasion assay confirmed the antimetastatic potential of compounds 14d and 15. Consistently with its ability to inhibit heparanase, compound 15 proved to decrease expression of genes encoding for proangiogenic factors such as MMP-9, VEGF, and FGFs in tumor cells.

U2 - 10.1021/acs.jmedchem.8b00908

DO - 10.1021/acs.jmedchem.8b00908

M3 - Article

C2 - 30010344

VL - 61

SP - 6918

EP - 6936

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 15

ER -